Skip to content

Initiative for Clinical Long-read Sequencing

Initiative for Clinical Long-read Sequencing - Towards Implementation of Long-read Genome Sequencing in Routine Diagnostics

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06060184
Acronym
IonGER
Enrollment
500
Registered
2023-09-29
Start date
2023-12-01
Completion date
2026-12-01
Last updated
2023-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Genetic Predisposition

Keywords

Long-read sequencing, Rare diseases, Cancer preposition, Translate-NAMSE, German initiative for genomic medicine (genomDE)

Brief summary

The study aims to comprehensively introduce Long-read Genome sequencing (LR-GS) based genetic testing into clinical routine. In order to demonstrate the superiority of untargeted LR-GS over Short-read Genome sequencing (SR-GS) to establish firm genetic diagnoses, the investigators will rely on a multi-center Translate Nationale Aktionsbündnis für Menschen mit Seltenen Erkrankungen (Translate National Action Alliance for People with Rare Diseases Germany, TNAMSE) cohort of unsolved patients with neurological, neurodevelopmental, and imprinting disorders that is expectedly enriched for complex genomic variation. Within the framework of genomDE, the investigators will then implement, for the first time, LR-GS in the diagnostic work-up of a prospective cohort of patients with a broad range of clinical indications including rare diseases and cancer predisposition.

Detailed description

The proposed study aims to develop a blueprint for the implementation of LR-GS in clinical diagnostics. Hence Standard Operating Procedures (SOPs) and guidelines for library preparation, bioinformatic analysis, and clinical interpretation will be compiled. Furthermore, the investigators intend to develop an open source 'gold standard' bioinformatics pipeline, addressing all relevant types of genomic alterations, thus providing the bioinformatic basis for a streamlined implementation of LR-GS at other sites. In addition to in-depth phenotype information the availability of SR-GS will be instrumental to benchmark the ability to detect different types of genomic variation. Additional relevant issues for genetic testing such as variant calling in difficult-to-map genomic regions, detection of genomic methylation patterns, characterization of repeat expansion and duplicated genes, and haplotype-phased genome de novo assembly will be addressed. Moreover, based on the strong background in Artificial Intelligence (AI) driven variant prioritization in the consortium, the investigators aim to implement and/or develop tools that enable an efficient prioritization of disease-causing variants. Beyond the usage within the context of the proposed study, generated datasets will be made available according to the Findable, Accessible, Interoperable and Reusable (FAIR) principles for national (German Human Genome-Phenome Archive, GHGA) and international (European Genome-Phenome Archive, EGA, Genome-Phenome Analysis Platform, GPaP) data repositories. the investigators aim to establish a population scale reference dataset for Structural variants (SV), which is absolutely mandatory in the context of rare disease diagnostics.

Interventions

Sequencing of genomes (Long read NGS)

Sponsors

RWTH Aachen University
CollaboratorOTHER
Medical University of Hannover
CollaboratorOTHER
Charite University, Berlin, Germany
CollaboratorOTHER
University Hospital Tuebingen
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

Parallel Assignment

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Unclear molecular cause of the disease (retrospective cohort) * Indication for genome diagnostics (prospective cohort; e.g. within the initiative for genomic medicine (genomDE) based on §64e SGB V) * Suspected genetic cause of the disease

Exclusion criteria

\- Missing informed consent of the patient or legal guardian

Design outcomes

Primary

MeasureTime frameDescription
Number of patients with Rare Disease (RD) or cancer predisposition syndromes with confirmed diagnosis by LR-GS compared to previous diagnostic methods including SR-GSDay 1A molecular diagnosis is considered confirmed when likely pathogenic or pathogenic variants are identified according to the American College of Medical Genetics and Genomics (ACMG). classification.

Countries

Germany

Contacts

Primary ContactTobias Haack, Dr.
tobias.haack@med.uni-tuebingen.de+49 7071 29
Backup ContactOlaf Rieß, Prof. Dr.
olaf.riess@med.uni-tuebingen.de+49 7071 29

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026